GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach

GSK PLC (LSE: GSK, NYSE: GSK) has secured regulatory approval in China for Nucala (mepolizumab) as an add-on maintenance therapy for adult patients with chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophil counts. The decision by China’s National Medical Products Administration marks the first greenlight for a monthly biologic in China targeting eosinophilic COPD, placing GSK ahead of rivals AstraZeneca and Sanofi/Regeneron in this subsegment.

The approval is anchored in data from the phase III METREX and MATINEE trials, where Nucala significantly reduced moderate and severe exacerbations in COPD patients with eosinophilic inflammation. The drug’s expanded indication complements GSK’s existing respiratory franchise in China, which includes asthma and chronic rhinosinusitis with nasal polyps.

Why Nucala’s COPD approval gives GSK a strategic respiratory edge in the China biologics market

The Chinese COPD population, which is estimated at over 100 million, is one of the largest globally. Despite this burden, biologic options for inflammatory phenotypes like eosinophilic COPD have been limited, particularly for patients who continue to deteriorate on inhaled triple therapy. By securing first-mover advantage with Nucala, GSK is capitalizing on a high-unmet-need subgroup where around 67% of inadequately controlled COPD patients show elevated blood eosinophils (BEC ≥150 cells/µL).

Unlike earlier biologics approved for asthma, Nucala’s monthly subcutaneous administration simplifies the treatment paradigm, particularly in outpatient settings. This is important in China’s healthcare landscape, where access to routine specialist biologic administration is often concentrated in tier-1 cities. A monthly dosing schedule reduces the logistical burden on both patients and the healthcare system.

GSK’s move also reflects a global trend toward biomarker-driven respiratory care. The ability to segment COPD patients by eosinophilic phenotype allows for more targeted interventions, reducing exacerbations that often lead to hospitalizations. This has meaningful implications not only for patient outcomes, but also for reducing the direct medical costs associated with frequent emergency visits and hospital admissions, both of which remain major cost drivers in chronic respiratory care.

What do the METREX and MATINEE trials reveal about mepolizumab’s performance in COPD?

The approval rests on two pivotal studies. In the MATINEE trial, Nucala reduced annualized exacerbation rates (AER) in patients with type 2 inflammation on inhaled triple therapy, achieving a rate ratio of 0.79 compared with placebo. Notably, the therapy cut exacerbations requiring emergency department visits or hospital admissions by 35% (rate ratio 0.65), a key secondary endpoint.

In the METREX trial, similar efficacy trends emerged, with an AER reduction of 0.31 versus placebo in the eosinophilic phenotype subgroup. Importantly, both trials enrolled patients with BEC starting from as low as 150 cells/µL—making Nucala the first biologic in China backed by data across a broad eosinophilic COPD population.

Safety profiles remained comparable to placebo, strengthening the case for Nucala as a low-risk, high-reward maintenance option.

Could biologics like Nucala reshape COPD treatment standards in China’s primary care system?

While GSK’s approval is a significant regulatory win, the broader adoption of Nucala will hinge on multiple factors. One challenge is the uneven availability of blood eosinophil testing across China. Outside urban hospitals, routine access to such diagnostics remains limited, which could restrict biomarker-based patient selection and real-world prescribing.

However, the inclusion of eosinophil count testing into COPD care pathways could gradually be normalized, particularly if supported by medical education initiatives and reimbursement alignment. Nucala’s monthly dosing model also positions it as a pragmatic option for integration into community-based or secondary-tier care facilities, expanding its accessibility footprint beyond top-tier respiratory centers.

Should GSK achieve early traction in metropolitan pilot programs or through inclusion in provincial reimbursement schemes, it could set a precedent for broader biologic adoption in inflammatory COPD—an area currently underserved by traditional small-molecule inhaled therapies.

How does GSK’s lead position compare with other COPD biologics in the Chinese pipeline?

While AstraZeneca’s benralizumab and Sanofi/Regeneron’s dupilumab have active or completed COPD trials, neither has yet secured COPD approval in China. Both agents target different pathways—IL-5 receptor and IL-4/13 respectively—but share GSK’s ambition to address exacerbation-prone patients with eosinophilic inflammation.

What gives GSK a tactical edge is its ability to leverage a well-established infrastructure in China for biologic distribution, a growing respiratory portfolio, and experience navigating local regulatory pathways through previous approvals of Nucala for severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).

Moreover, GSK’s decision to seek COPD approval in a broad BEC population starting at 150 cells/µL rather than the traditionally higher 300 threshold used in earlier asthma studies, reflects a market-tailored strategy that better aligns with the real-world inflammatory profiles observed in Chinese COPD cohorts.

What does this approval signal about GSK’s wider respiratory R&D and capital allocation?

GSK continues to place strategic emphasis on type 2 inflammation as a cross-indication axis for respiratory growth. With Nucala now approved in four indications in China, the company is strengthening its ability to cross-leverage clinical and market access infrastructure while supporting its broader late-stage R&D pipeline.

In the backdrop of GSK’s post-Haleon spinoff identity as a leaner biopharma company focused on vaccines and specialty medicines, approvals like this help reinforce its respiratory and immunology thesis. Capital allocation into biologics with high differentiation and reimbursement potential also fits into GSK’s broader narrative of reducing dependence on traditional primary care markets and leaning into specialist-driven growth segments.

Institutional investors are likely to view this regulatory milestone as validation of GSK’s China execution capability—a theme that has often been underweighted in sentiment compared to peers more exposed to oncology or mRNA assets.

What comes next for mepolizumab and other respiratory biologics in global COPD strategy?

Beyond China, GSK is seeking further expansion of Nucala’s COPD label across other geographies. The drug recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), paving the way for potential approval in the European Union. In the United States, Nucala is already approved for COPD and other eosinophilic conditions.

Looking forward, the company may explore real-world evidence generation and health economic models to support reimbursement submissions in additional Asian and emerging markets. If successful, this could widen access and accelerate the normalization of biologics in high-burden COPD care.

Should competitors eventually receive COPD approvals, GSK will benefit from first-mover brand entrenchment, prescriber familiarity, and a head start in navigating biomarker testing adoption—all factors that could help preserve pricing power and commercial momentum even in a crowded market.

Key takeaways: What GSK’s Nucala COPD approval in China means for respiratory biologics

• GSK secured Chinese approval for Nucala (mepolizumab) in adult COPD patients with elevated eosinophils, marking the first monthly biologic in this indication.

• The approval is based on positive outcomes from the phase III METREX and MATINEE trials showing significant reduction in exacerbation rates.

• Nucala addresses a high-unmet-need COPD subgroup where around 67% of patients on triple therapy have elevated eosinophils.

• Monthly dosing and biomarker-based targeting align with China’s evolving healthcare delivery capabilities and outpatient management needs.

• Adoption could be limited in rural areas due to uneven access to blood eosinophil testing, but pilot programs and reimbursement may expand reach.

• GSK’s first-mover advantage strengthens its respiratory franchise in China ahead of potential approvals for benralizumab and dupilumab.

• Regulatory success reinforces GSK’s type 2 inflammation platform and supports its specialty medicine pivot post-Haleon spinout.

• Investor sentiment may improve as GSK demonstrates consistent regulatory wins in growth markets like China.